These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24654822)

  • 1. Over-expression of EGFR is closely correlated to poor prognosis in Tunisian patients with non-small cell lung adenocarcinoma.
    Arfaoui A; Kriaa L; Znaidi N; Gritli S; Bouacha H; Zermani R; Rammeh S
    J Immunoassay Immunochem; 2014; 35(3):256-68. PubMed ID: 24654822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FHIT, EGFR, and MSH2: possible etiopathologic, prognostic, and predictive role in non-small cell lung carcinoma in Egyptian patients.
    Younes SF; Aiad HA; Asaad NY; Kandil MA; Natkunam Y; Mokhtar NM
    Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):275-83. PubMed ID: 24185125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hsp90AB1 Protein is Overexpressed in Non-small Cell Lung Cancer Tissues 
and Associated with Poor Prognosis in Lung Adenocarcinoma Patients].
    Wang M; Feng L; Li P; Han N; Gao Y; Xiao T
    Zhongguo Fei Ai Za Zhi; 2016 Feb; 19(2):64-9. PubMed ID: 26903158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
    Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
    Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patients.
    Molinier O; Goupil F; Debieuvre D; Auliac JB; Jeandeau S; Lacroix S; Martin F; Grivaux M
    Respir Med Res; 2020 Mar; 77():46-54. PubMed ID: 32036284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
    Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
    BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis.
    Yang SL; Ren QG; Wen L; Hu JL
    J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):321-327. PubMed ID: 27376798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CIP4 promotes lung adenocarcinoma metastasis and is associated with poor prognosis.
    Truesdell P; Ahn J; Chander H; Meens J; Watt K; Yang X; Craig AW
    Oncogene; 2015 Jul; 34(27):3527-35. PubMed ID: 25174397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal Growth Factor Receptor Gene Amplification Predicts Worse Outcome in Patients With Surgically Resected Nonadenocarcinoma Lung Cancer.
    Chang H; Yang Y; Lee JS; Jheon SH; Kim YJ; Chung JH
    Clin Lung Cancer; 2019 Jan; 20(1):7-12.e1. PubMed ID: 30017644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma.
    Kim Y; Shiba-Ishii A; Nakagawa T; Husni RE; Sakashita S; Takeuchi T; Noguchi M
    Pathol Int; 2017 Jun; 67(6):292-301. PubMed ID: 28544031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations.
    Kriegsmann M; Harms A; Kazdal D; Fischer S; Stenzinger A; Leichsenring J; Penzel R; Longuespée R; Kriegsmann K; Muley T; Safi S; Warth A
    Pathol Res Pract; 2018 Mar; 214(3):408-416. PubMed ID: 29487011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of an EGFR mutation in cytological specimens of lung adenocarcinoma.
    Mohar B; Smojver Ježek S; Rajković Molek K; Štemberger C; Kurpis M; Kupanovac Ž; Samaržija M; Jonjić N; Grahovac B
    Cytopathology; 2016 Dec; 27(6):444-451. PubMed ID: 26990359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
    Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations.
    Xu L; Lei J; Wang QZ; Li J; Wu L
    Genet Mol Res; 2015 Oct; 14(4):12973-83. PubMed ID: 26505450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
    Wang D; Zhang M; Gao X; Yu L
    PLoS One; 2016; 11(6):e0158307. PubMed ID: 27336755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations.
    Park JY; Jang SH; Kim HI; Kim JH; Park S; Hwang YI; Jung KS; Seo J; Lee CY; Ko Y; Park YB
    BMC Cancer; 2019 Jun; 19(1):574. PubMed ID: 31196060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
    Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.